

TDMS No. 93025 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 05/22/2008

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

C Number: C93025

Lock Date: 03/22/2006

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Both

TDMSE Version: 2.0.0

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	30 PPM	60 PPM	120 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	9	8	7	11
Natural Death	5	7	5	3
Survivors				
Terminal Sacrifice	36	35	38	36
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Gallbladder	(43)	(41)	(43)	(41)
Intestine Large, Cecum	(47)	(45)	(45)	(47)
Intestine Small, Duodenum	(45)	(45)	(45)	(47)
Polyp Adenomatous		1 (2%)		1 (2%)
Intestine Small, Ileum	(47)	(44)	(45)	(47)
Intestine Small, Jejunum	(45)	(44)	(45)	(47)
Carcinoma		1 (2%)		1 (2%)
Liver	(49)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	3 (6%)		1 (2%)
Hepatocellular Adenoma	18 (37%)	13 (26%)	16 (32%)	14 (28%)
Hepatocellular Adenoma, Multiple	15 (31%)	18 (36%)	19 (38%)	13 (26%)
Hepatocellular Carcinoma	11 (22%)	14 (28%)	11 (22%)	13 (26%)
Hepatocellular Carcinoma, Multiple		3 (6%)	3 (6%)	1 (2%)
Hepatocholangiocarcinoma, Multiple		1 (2%)		
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Mesentery	(13)	(4)	(10)	(2)
Pancreas	(49)	(49)	(50)	(50)
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Stomach, Forestomach	(49)	(48)	(50)	(50)
Squamous Cell Papilloma				1 (2%)
Stomach, Glandular	(49)	(47)	(48)	(48)
Tooth	(7)	(6)	(7)	(1)
Odontoma	1 (14%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	30 PPM	60 PPM	120 PPM
CARDIOVASCULAR SYSTEM				
Blood Vessel	(0)	(0)	(0)	(1)
Heart	(50)	(50)	(50)	(50)
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(49)	(50)	(50)
Adenoma	1 (2%)		1 (2%)	
Capsule, Adenoma	1 (2%)			2 (4%)
Capsule, Carcinoma		1 (2%)		
Adrenal Medulla	(47)	(49)	(49)	(50)
Pheochromocytoma Benign	1 (2%)	1 (2%)		
Islets, Pancreatic	(49)	(48)	(50)	(50)
Adenoma	2 (4%)			
Carcinoma			1 (2%)	
Pituitary Gland	(50)	(49)	(48)	(49)
Pars Distalis, Adenoma		1 (2%)		
Thyroid Gland	(49)	(49)	(49)	(50)
GENERAL BODY SYSTEM				
Peritoneum	(0)	(1)	(0)	(0)
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (100%)		
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Preputial Gland	(50)	(50)	(49)	(50)
Prostate	(49)	(48)	(49)	(49)
Seminal Vesicle	(49)	(47)	(48)	(48)
Testes	(50)	(50)	(50)	(50)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(49)
Hemangiosarcoma		1 (2%)		2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	30 PPM	60 PPM	120 PPM
Lymph Node	(1)	(0)	(0)	(0)
Lymph Node, Bronchial	(35)	(30)	(22)	(27)
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (3%)		
Lymph Node, Mandibular	(24)	(26)	(28)	(25)
Sarcoma, Metastatic, Uncertain Primary Site				1 (4%)
Lymph Node, Mediastinal	(34)	(36)	(34)	(33)
Hepatocarcinoma, Metastatic, Liver		1 (3%)		
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (3%)		
Lymph Node, Mesenteric	(47)	(48)	(48)	(48)
Plasma Cell Tumor Malignant			1 (2%)	
Spleen	(49)	(49)	(49)	(49)
Hemangiosarcoma	1 (2%)			2 (4%)
Thymus	(47)	(40)	(45)	(43)
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (3%)		
INTEGUMENTARY SYSTEM				
Skin	(50)	(49)	(50)	(50)
Subcutaneous Tissue, Fibrous	1 (2%)	1 (2%)		
Histiocytoma				
Subcutaneous Tissue, Hemangioma	1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Subcutaneous Tissue, Sarcoma	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(49)
Skeletal Muscle	(0)	(1)	(0)	(0)
Hepatocarcinoma, Metastatic, Liver		1 (100%)		
NERVOUS SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	30 PPM	60 PPM	120 PPM
Brain	(50)	(50)	(50)	(50)
Spinal Cord	(1)	(0)	(0)	(0)
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	10 (20%)	5 (10%)	6 (12%)	8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple		1 (2%)		
Alveolar/Bronchiolar Carcinoma	11 (22%)	5 (10%)	11 (22%)	6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple		2 (4%)	1 (2%)	2 (4%)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Carcinoma, Metastatic, Kidney		1 (2%)		
Hemangiosarcoma			1 (2%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	4 (8%)	9 (18%)	5 (10%)	6 (12%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)
Nose	(49)	(49)	(50)	(50)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)
Trachea	(49)	(48)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(48)	(46)	(47)	(47)
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)
Harderian Gland	(49)	(47)	(50)	(50)
Adenoma	2 (4%)	5 (11%)	4 (8%)	1 (2%)
Carcinoma	3 (6%)	3 (6%)		1 (2%)
Sarcoma		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	30 PPM	60 PPM	120 PPM
URINARY SYSTEM				
Kidney	(49)	(49)	(50)	(49)
Carcinoma, Metastatic, Intestine Small, Jejunum		1 (2%)		
Renal Tubule, Adenoma		1 (2%)		
Transitional Epithelium, Carcinoma		1 (2%)		
Urinary Bladder	(49)	(47)	(50)	(48)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Lymphoma Malignant	2 (4%)	1 (2%)	4 (8%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	CONTROL	30 PPM	60 PPM	120 PPM
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	47	45	46	42
Total Primary Neoplasms	85	85	80	73
Total Animals with Benign Neoplasms	42	36	38	31
Total Benign Neoplasms	52	46	46	40
Total Animals with Malignant Neoplasms	26	26	24	25
Total Malignant Neoplasms	33	39	34	33
Total Animals with Metastatic Neoplasms	5	12	5	7
Total Metastatic Neoplasms	5	21	5	11
Total Animals with Malignant Neoplasms Uncertain Primary Site		1		1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	30 PPM	60 PPM	120 PPM
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	17	9	6	6
Natural Death	2	3	2	1
Survivors				
Terminal Sacrifice	31	38	42	43
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(42)	(43)	(44)	(47)
Intestine Large, Colon	(49)	(49)	(49)	(48)
Leiomyosarcoma	1 (2%)			
Intestine Small, Duodenum	(48)	(48)	(48)	(49)
Leiomyosarcoma	1 (2%)			
Polyp Adenomatous				1 (2%)
Intestine Small, Ileum	(48)	(48)	(49)	(49)
Polyp Adenomatous	1 (2%)		1 (2%)	
Intestine Small, Jejunum	(48)	(48)	(48)	(49)
Carcinoma			1 (2%)	1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)			1 (2%)
Hepatocellular Adenoma	10 (20%)	13 (26%)	14 (28%)	14 (28%)
Hepatocellular Adenoma, Multiple	4 (8%)	3 (6%)	3 (6%)	8 (16%)
Hepatocellular Carcinoma	5 (10%)	4 (8%)	5 (10%)	2 (4%)
Hepatocellular Carcinoma, Multiple	2 (4%)	1 (2%)	4 (8%)	
Osteosarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Mesentery	(16)	(17)	(15)	(10)
Hemangiosarcoma	1 (6%)			
Pancreas	(50)	(50)	(50)	(50)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	30 PPM	60 PPM	120 PPM
Hemangiosarcoma			1 (2%)	
Luteoma	1 (2%)		1 (2%)	1 (2%)
Teratoma Benign	1 (2%)			
Teratoma Malignant	1 (2%)			
Uterus	(50)	(50)	(50)	(50)
Adenoma	1 (2%)			
Carcinoma	1 (2%)			1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
Hemangiosarcoma	1 (2%)	1 (2%)		1 (2%)
Leiomyosarcoma	1 (2%)			
Polyp Stromal	1 (2%)	3 (6%)	4 (8%)	
Sarcoma Stromal		1 (2%)		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(49)
Hemangiosarcoma	1 (2%)			2 (4%)
Lymph Node	(7)	(7)	(3)	(2)
Lymph Node, Bronchial	(33)	(32)	(28)	(37)
Lymph Node, Mandibular	(33)	(34)	(30)	(31)
Hemangiosarcoma	1 (3%)			
Lymph Node, Mediastinal	(35)	(42)	(38)	(35)
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site	1 (3%)			
Osteosarcoma, Metastatic, Uncertain Primary Site	1 (3%)			
Lymph Node, Mesenteric	(49)	(48)	(49)	(50)
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
Teratoma Malignant, Metastatic, Ovary	1 (2%)			
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)		1 (2%)	4 (8%)
Mast Cell Tumor Malignant, Metastatic, Uncertain Primary Site	1 (2%)			
Thymus	(48)	(49)	(49)	(47)
INTEGUMENTARY SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	30 PPM	60 PPM	120 PPM
Mammary Gland	(50)	(49)	(50)	(50)
Carcinoma	1 (2%)	2 (4%)		
Skin	(50)	(50)	(50)	(50)
Sebaceous Gland, Adenoma	1 (2%)			1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma		1 (2%)		
Subcutaneous Tissue, Hemangiosarcoma		1 (2%)	1 (2%)	
Subcutaneous Tissue, Sarcoma	1 (2%)	1 (2%)		1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			1 (2%)
Skeletal Muscle	(1)	(0)	(1)	(1)
Hemangiosarcoma	1 (100%)			
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(49)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	6 (12%)	1 (2%)	2 (4%)	4 (8%)
Alveolar/Bronchiolar Carcinoma		4 (8%)	2 (4%)	2 (4%)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	3 (6%)	1 (2%)	4 (8%)	1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Mediastinum, Hemangiosarcoma	1 (2%)			
Nose	(50)	(50)	(50)	(49)
Pleura	(1)	(0)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	30 PPM	60 PPM	120 PPM
Osteosarcoma, Metastatic, Uncertain Primary Site	1 (100%)			
Trachea	(50)	(50)	(50)	(49)
SPECIAL SENSES SYSTEM				
Eye	(49)	(49)	(49)	(49)
Harderian Gland	(50)	(50)	(49)	(49)
Adenoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Carcinoma	1 (2%)		1 (2%)	
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Renal Tubule, Adenoma		1 (2%)		
Urinary Bladder	(49)	(50)	(49)	(49)
Carcinoma, Metastatic, Uncertain Primary Site				1 (2%)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Lymphoma Malignant	12 (24%)	12 (24%)	10 (20%)	12 (24%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Tetralin

Time Report Requested: 06:34:08

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 119-64-2

First Dose M/F: 06/23/03 / 06/23/03

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	CONTROL	30 PPM	60 PPM	120 PPM
Tumor Summary for Females				
Total Animals with Primary Neoplasms (b)	39	38	38	43
Total Primary Neoplasms	77	63	64	74
Total Animals with Benign Neoplasms	24	27	26	34
Total Benign Neoplasms	37	32	37	43
Total Animals with Malignant Neoplasms	25	25	23	23
Total Malignant Neoplasms	40	31	27	31
Total Animals with Metastatic Neoplasms	7	1	5	1
Total Metastatic Neoplasms	12	1	5	9
Total Animals with Malignant Neoplasms Uncertain Primary Site	2			1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors